523 related articles for article (PubMed ID: 28376855)
1. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.
Fadini GP; Bonora BM; Zatti G; Vitturi N; Iori E; Marescotti MC; Albiero M; Avogaro A
Cardiovasc Diabetol; 2017 Apr; 16(1):42. PubMed ID: 28376855
[TBL] [Abstract][Full Text] [Related]
2. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type.
Bechmann LE; Emanuelsson F; Nordestgaard BG; Benn M
Atherosclerosis; 2024 Jul; 394():117236. PubMed ID: 37582673
[TBL] [Abstract][Full Text] [Related]
3. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
[TBL] [Abstract][Full Text] [Related]
4. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial.
Yamakage H; Tanaka M; Inoue T; Odori S; Kusakabe T; Satoh-Asahara N
J Diabetes Investig; 2020 May; 11(3):653-661. PubMed ID: 31721467
[TBL] [Abstract][Full Text] [Related]
5. Impact of 24-week dapagliflozin treatment on body weight, body composition, and cardiac risk indicators of patients with type-2 diabetes mellitus.
Akhanli P; Hepşen S; Arslan İE; Düğer H; Bostan H; Kizilgül M; Uçan B; Çakal E
Turk J Med Sci; 2023; 53(5):1178-1184. PubMed ID: 38813008
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress.
Shyr ZA; Yan Z; Ustione A; Egan EM; Remedi MS
PLoS One; 2022; 17(2):e0258054. PubMed ID: 35180212
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin-Induced Myocardial Flow Reserve Improvement is not Associated with HDL Ability to Stimulate Endothelial Nitric Oxide Production.
Capece U; Pavanello C; Cinti F; Leccisotti L; Mezza T; Ciccarelli G; Moffa S; Di Giuseppe G; Soldovieri L; Brunetti M; Giordano A; Giaccari A; Calabresi L; Ossoli A
Diabetes Ther; 2024 Jan; 15(1):257-268. PubMed ID: 37883003
[TBL] [Abstract][Full Text] [Related]
8. Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study.
Pitsiava S; Dimakopoulos G; Tsimihodimos V; Kotsa K; Koufakis T
Expert Opin Pharmacother; 2024 Jun; 25(8):1095-1104. PubMed ID: 38822807
[TBL] [Abstract][Full Text] [Related]
9. Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients.
Ohashi N; Aoki T; Matsuyama T; Ishigaki S; Isobe S; Fujikura T; Hashimoto T; Tsuriya D; Morita H; Kato A; Yasuda H
Med Sci Monit; 2020 Oct; 26():e926086. PubMed ID: 33004785
[TBL] [Abstract][Full Text] [Related]
10. Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice.
Di Vincenzo A; Crescenzi M; Granzotto M; Vecchiato M; Fioretto P; Vettor R; Rossato M
J Endocrinol Invest; 2024 Jul; 47(7):1777-1786. PubMed ID: 38194168
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin Reduces Systemic Inflammation in Patients with Type 2 Diabetes Without Known Heart Failure.
Wang D; Naumova A; Isquith D; Sapp J; Huynh KA; Tucker I; Balu N; Voronyuk A; Chu B; Ordovas K; Maynard C; Tian R; Zhao XQ; Kim F
Res Sq; 2024 Mar; ():. PubMed ID: 38585865
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of adding Dapagliflozin in patients with nephrotic syndrome.
ElSharkawy M; Emara A; Ahmed MM; Ghonamy E; Teama NM
Int Urol Nephrol; 2024 Jun; ():. PubMed ID: 38862701
[TBL] [Abstract][Full Text] [Related]
13. The impact of dapagliflozin on glucose excursions related to early proatherogenic derangement in the aortic wall.
Stelmaszyk A; Wesołowska A; Pomieczyńska K; Iskakova S; Frydrychowicz M; Dworacki G; Dworacka M
Saudi Pharm J; 2018 Dec; 26(8):1192-1198. PubMed ID: 30510471
[TBL] [Abstract][Full Text] [Related]
14. Correction: Effects of Bariatric Surgery on HDL Cholesterol.
Genua I; Ramos A; Caimari F; Balagué C; Sánchez-Quesada JL; Pérez A; Miñambres I
Obes Surg; 2024 Jun; 34(6):2284. PubMed ID: 38710974
[No Abstract] [Full Text] [Related]
15. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Zinman B; Inzucchi SE; Lachin JM; Wanner C; Fitchett D; Kohler S; Mattheus M; Woerle HJ; Broedl UC; Johansen OE; Albers GW; Diener HC;
Stroke; 2017 May; 48(5):1218-1225. PubMed ID: 28386035
[TBL] [Abstract][Full Text] [Related]
18. The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Kato K; Suzuki K; Aoki C; Sagara M; Niitani T; Wakamatsu S; Yanagi K; Aso Y
Expert Opin Pharmacother; 2017 Jun; 18(8):743-751. PubMed ID: 28426260
[TBL] [Abstract][Full Text] [Related]
19. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Cha SA; Park YM; Yun JS; Lim TS; Song KH; Yoo KD; Ahn YB; Ko SH
Lipids Health Dis; 2017 Apr; 16(1):58. PubMed ID: 28403877
[TBL] [Abstract][Full Text] [Related]
20. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Brown AJM; Lang C; McCrimmon R; Struthers A
BMC Cardiovasc Disord; 2017 Aug; 17(1):229. PubMed ID: 28835229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
